Kevin has more than 20 years of experience in the high tech and biotech industries combined, 15 years of which have most recently been in the biotech industry with both large commercial and small emerging companies. He joined Versartis as a consultant in December 2013, became the Corporate Controller in January 2014 prior to the Company’s IPO and served in that capacity until December 2017. Kevin joined Versartis from InterMune, Inc., where he spent 8 years. Prior to its acquisition by Roche Holdings, Inc., he served in various financial management roles, including Director of Financial Reporting and most recently as Director of Financial Planning, where he was instrumental in building out the finance infrastructure in preparation for the European launch of Esbriet®. Prior to his tenure at Intermune, Kevin spent three years at Gilead Sciences, Inc. through the approval and launch of Viread®. He also spent eight years at Cisco Systems, Inc. in various capacities in finance, including a central role where he lead the financial integration of in excess of thirty acquisitions during a period of rapid growth. He began his career in public accounting with Grant Thornton, LLP. Kevin holds a B.S. in Business Administration, emphasis Accounting, from Western State Colorado University, where he graduated cum laude and was an Academic All-American in the sport of basketball his senior year.
Vice President, Finance